For Surgeons
Lumicell is changing the landscape of cancer surgery with a hand-held imaging system that enables surgeons to identify any cancer cells left behind on the tumor cavity walls and take action in real-time to improve patient outcomes.
For Patients
Lumicell is addressing the number one challenge in cancer surgery – the need to remove all cancer cells during the first surgery while preserving healthy tissue.
News
Kevin Hershberger Joins Lumicell as Chief Financial Officer
Hershberger brings over 25 years of global financial management experience from a variety of life science products and manufacturing companies
Lumicell Expands Board with Addition of Michael Ruettgers
Industry executive with history of building successful Boston-based businesses will serve as an advisor to the development of Lumicell’s growth and long-term business strategies
Lumicell Launches Wound Care Infection and Perfusion Division
New business unit aims to tackle challenges around chronic wounds
Lumicell Forms Scientific Advisory Board To Drive Future Innovations
Members will serve as key advisors and foundational partners in the development of Lumicell technology
CEO Today officially announced the full list of finalists and, of course, the winners of their 2018 Business Women of the Year Awards. Proud to have Lumicell's own CEO, Kelly Londy, featured!
Lumicell Reports Positive Clinical Results with LUM System Demonstrating Rapid Identification of Residual Tumor in Lumpectomy Cavity of Patients with Breast Cancer
Data Published by Investigators at Massachusetts General Hospital in the Journal of Breast Cancer Research and Treatment
Catching Every Cancer Cell While in Surgery
A veterinary surgeon at Tufts tests and experimental imaging technology on dogs being treated for cancer
This New Technology Could Help Surgeons Clear Out Leftover Cancer Cells
In some instances, as many as 30% of patients need repeat surgeries to get rid of cancerous cells initially left behind. The team from Lumicell wants to change that — and improve outcomes for cancer patients.
Lumicell Presents Phase 2 Clinical Data Showing LUM System Provided Complete and Immediate Detection of Residual Cancer in Tumor Cavity During Lumpectomy Surgery
Data Presented by Investigators from Massachusetts General Hospital's Breast Program at 2017 San Antonio Breast Cancer Symposium Integrated LUM System Correctly Identified Residual Cancer Cells Across Breast Cancer Subtypes
Lumicell Expands Development Strategy and Pipeline Across Five Solid Tumor Cancers Supported by $28.7 Million Series C Financing
Proceeds to Fund Pivotal Trial in Breast Cancer Leverages Broad Potential of LUM System with Drug, Device and Software for Real-time Detection of Tumor Tissue in Patients During Surgery